原标题:康方生物-B新药进展 来源:每日经济新闻每经AI快讯,康方生物-B董事会宣布,公司核心自主研发的、全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号:AK104)获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,用于治疗宫颈癌(除极早期IA1期之外)。(记者 袁东)免责声明:本文内容与数据仅供参考,不构成投资建议,使用前...
Source Link原标题:康方生物-B新药进展 来源:每日经济新闻每经AI快讯,康方生物-B董事会宣布,公司核心自主研发的、全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号:AK104)获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,用于治疗宫颈癌(除极早期IA1期之外)。(记者 袁东)免责声明:本文内容与数据仅供参考,不构成投资建议,使用前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.